Biodegradable medical implants, polymer compositions and methods of use

Abstract

Embodiments of the invention provide compositions including bio degradable polymers, medical implants fabricated from these compositions and methods of using such implants. Many embodiments provide medical implants comprising a first polymer backbone having a first rate of biodegradation and a second polymer backbone having a second rate of biodegradation faster than the first rate. In some embodiments, the second backbone is configured to be replaced by a natural tissue layer. The first backbone provides a scaffold for the implant while the second backbone degrades. This scaffold can enhance mechanical properties of the implant including various aspects of mechanical strength such as tensile, bending, hoop and yield strength; and elasticity. The scaffold also serves to maintain a minimum level of structural support of the implant during the period of degradation of the second backbone or for the entire life of the implant so that the implant does not mechanically fail.

1 - 37 . (canceled) 
     
     
         38 . A biodegradable medical implant for implantation in the human body, the implant comprising a polymer composition comprising a mixture of:
 a first polymer backbone having a first rate of biodegradation, the first polymer backbone comprising a polyurethane;   a second polymer backbone cross-linked to the first polymer backbone and having a second rate of biodegradation faster than the first rate of biodegradation, wherein the second polymer comprises polyglycolic acid (PGA) or polyglycolic lactic acid (PGLA), wherein a weight ratio of polyurethane to PGLA or PGA in the composition ranges from about 20:80 to 80:20, wherein the degradation rates of the first and second polymer backbone are configured such that the first polymer backbone provides a scaffold for the implant that is maintained while the second polymer backbone degrades; and   a cell adhesion and migration promoting polypeptide (CAMPP) cross-linked to the first polymer backbone wherein the cell adhesion and migration promoting polypeptide is configured to promote the adhesion and migration of a confluent layer of cells on a surface of the implant.   
     
     
         39 . The implant of  claim 38 , wherein the cell adhesion and migration promoting polypeptide is configured to promote the adhesion and migration of a confluent layer of cells on a surface of the implant the confluent layer of cells comprising endothelial or smooth muscle cells. 
     
     
         40 . The implant of  claim 38 , wherein the cell adhesion and migration promoting polypeptide is a multi-armed polypeptide or P-15 polypeptide. 
     
     
         41 . The implant of  claim 38 , wherein the cell adhesion and migration promoting polypeptide is cross-linked via an amino acid residue to a side chain of the first polymer backbone. 
     
     
         42 . The implant of  claim 38 , wherein the cell adhesion and migration promoting polypeptide is cross-linked via a tyrosine residue to an isocyanate side chain of the first polymer backbone. 
     
     
         43 . The implant of  claim 38 , wherein the second rate of biodegradation is at least ten times faster than the first rate of biodegradation. 
     
     
         44 . The implant of  claim 38 , wherein the first polymer backbone and the second polymer backbone are cross-linked by a urethane linkage between an isocyanate side group on the first polymer backbone and a methylene side group on the second polymer backbone. 
     
     
         45 . The implant of  claim 38 , wherein at least 80% of a structure of the first polymer backbone remains within the human body during a life of the implant. 
     
     
         46 . The implant of  claim 38 , wherein the polymer composition is non-crystalline. 
     
     
         47 . The implant of  claim 38 , wherein the implant comprises a first portion including the first polymer backbone and a second portion including the second polymer backbone. 
     
     
         48 . The implant of  claim 47 , wherein the first portion comprises a first layer and the second portion comprises a second layer. 
     
     
         49 . The implant of  claim 48 , wherein the second layer overlies the first layer. 
     
     
         50 . The implant of  claim 47 , wherein the first portion comprises a central portion and the second portion abuts the first portion. 
     
     
         51 . The implant of  claim 38 , wherein an amount of cross-linking controls the second rate of biodegradation. 
     
     
         52 . The implant of  claim 38 , wherein the scaffold increases one of a tensile strength or a bending strength of the implant. 
     
     
         53 . The implant of  claim 52 , wherein the tensile strength of the implant ranges from about 0.7 to 3.8 lbs. 
     
     
         54 . The implant of  claim 38 , wherein the scaffold increases an elasticity of the implant. 
     
     
         55 . The implant of  claim 38 , wherein the scaffold increases a fracture resistance of the implant. 
     
     
         56 . The implant of  claim 38 , wherein the implant is a stent, a biliary stent, a vascular stent or a coronary artery stent. 
     
     
         57 . The implant of  claim 38 , wherein the implant is a graft, an intestinal graft, a vascular graft, an arterial graft or an aortic graft.